Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression

@article{Reid2001PredictorsOP,
  title={Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression},
  author={Brian J. Reid and Laura J. Prevo and Patricia C. Galipeau and Carissa A. Sanchez and Gary M. Longton and Douglas S. Levine and Patricia L. Blount and Peter S. Rabinovitch},
  journal={American Journal of Gastroenterology},
  year={2001},
  volume={96},
  pages={2839-2848}
}
OBJECTIVES:Most patients with Barrett's esophagus do not progress to cancer, but those who do seem to have markedly increased survival when cancers are detected at an early stage. Most surveillance programs are based on histological assessment of dysplasia, but dysplasia is subject to observer variation and transient diagnoses of dysplasia increase the cost… CONTINUE READING